Home » Posts tagged 'david navas'

Tag Archives: david navas

Proton Beam Therapy and CERN Hadron Technology Are Fighting Cancer With LIGHT

Article by Drew Turney at Autodesk Redshift

 

According to the US National Cancer Institute, nearly 40 percent of Americans will be diagnosed with cancer during their lives. The World Health Organisation names cancer as the second leading cause of death globally, causing nearly one in six deaths. In case anyone needs reminding, cancer is a big deal.

Alongside chemotherapy and surgery to remove tumors, about 40 percent of cancer patients are treated with radiotherapy, which fires ionizing radiation into the body, killing malignant cells with X-ray photons. Roughly 17,000 clinics worldwide deliver X-ray radiotherapy treatment today.

Traditional radiotherapy can damage surrounding tissues because it ionizes the body along its entire path, leading to the potentially serious side effects associated with cancer treatment—which is even more fraught when the cancer is located near a critical organ. Enter the proton, the positively charged particle found in the nuclei of atoms. Proton beam radiotherapy for cancer treatment, which has been in use as far back as 1954, promises more precise control of where it delivers energy to kill cancer cells.

Clearly, proton therapy is a much better method, but it’s only available in approximately 65 facilities worldwide. What’s wrong with this picture?

Using a Wrecking Ball to Hammer a Nail

The scientists who started Advanced Oncotherapy asked themselves the same question. Headquartered in London—with 90 staff in the UK, Switzerland, and the United States—the company is taking proton beam therapy into the new age with its novel proton beam therapy (PBT) system, LIGHT.

Initial research on the system originated from a program at CERN in Geneva, and ADAM, an Advanced Oncotherapy subsidiary spun off from CERN, was instrumental in the early stages. In fact, 60 of Advanced Oncotherapy’s scientific staff are based in Geneva. According to David Navas, Advanced Oncotherapy’s vice president of investor and corporate relations, the initial CERN technology is still a major asset for the company. “Having a license on a CERN technology that builds on decades of CERN experience in accelerators is enormously advantageous to ADAM and Advanced Oncotherapy,” he says.

Advanced Oncotherapy is on target to treat its first patient in 2020. Still, if this technology has been around since the 1950s, why is there development to be done? Quite simply, proton therapy costs too much, and it’s too technically inaccessible. “Current systems are based on cyclotrons or synchrotrons,” Navas says. “They have drawbacks inherent to the design of the accelerating system itself.”

Those systems can be large and heavy and must be manufactured and installed under very controlled (read: expensive) conditions. This can mean systems with the footprint of a sports field, impossible for most hospitals; although smaller accelerators exist, they suffer from the same inherent issues that all cyclotrons and synchrotrons do, such as slow beam-energy modulation that’s problematic for accurate targeting. Requiring a dedicated building plus accelerator equipment, which alone can cost upward of $100 million for multitreatment-room systems, it’s out of reach for most health-care bodies.

Advanced Oncotherapy Quality Manager Neil Barker recalls hearing of a synchrotron installation that required putting the machine in place and completing the building around it. “They couldn’t get an 800-ton crane, so they had to install it using two 500-ton cranes,” he says.

But Advanced Oncotherapy’s system is broken down into constituent parts—modules—and streamlined. An everyday bed lift could move all components, transporting them to the assembly point inside a clinic or specially adapted building, Barker says. That’s because the company is developing a linear accelerator rather than the traditional round shape. The world’s only linear accelerator for PBT, LIGHT offers several advantages over circular accelerators: It can take up less space; does not require expensive, complex cryogenic cooling; demands less shielding because stray radiation is reduced; and offers the ability to change energy levels rapidly on a pulse-by-pulse basis.

Link here to read the full article

Advanced Oncotherapy (AVO) – Major Shareholder increases stake

NOTIFICATION OF MAJOR INTEREST IN SHARES

 download movie War for the Planet of the Apes 2017

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Advanced Oncotherapy plc

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

 

3. Full name of person(s) subject to the notification obligation: iii

AB Segulah

4. Full name of shareholder(s)

(if different from 3.): iv

HSBC Global Custody Nominee (UK)

5. Date of the transaction and date on which the threshold is crossed or reached: v

20 March 2017

6. Date on which issuer notified:

20 March 2017

7. Threshold(s) that is/are crossed or

reached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirectxii

Direct

Indirect

Ordinary Shares GBP 0.25

 

GB00BD6SX109

3,505,451

3,505,451

3,680,451

3,680,451

5.06%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion
Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

 

% of voting
rights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise
price

Expiration
date
xvii

Exercise/
Conversion
period
xviii

Number of voting
rights instrument
refers to

% of voting rightsxix, xx

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 3,680,451

 5.06%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 

The 3,680,451 shares are held by HSBC Global Custody Nominee (UK) under direct control of AB Segulah.                                 

 

Proxy Voting:

10. Name of the proxy holder:

 N/A

11. Number of voting rights proxy holder will cease to hold:

 N/A

12. Date on which proxy holder will cease to hold voting rights:

 N/A

 

13. Additional information:

 N/A

14. Contact name:

 David Navas, AVO plc

15. Contact telephone number:

 020 3873 2051

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.